The US Food and Drug Administration (FDA) has determined the shortage of glucagon-like peptide 1 (GLP-1) medication, semaglutide, is resolved
The red transcript variants do not codify for any isoform
Coding and non-coding RNAs were differentially expressed: 92 were upregulated and 13 downregulated (P adj 20%, most of which (14,509) mapped to open sea regions of the genome
However, it seems to have a narrow therapeutic index with emergent dose-limiting toxicities, which leads to the discontinuation of the trials [117]
Usually mild and self-resolving within hours
Search Strategy and Study Selection This narrative review was conducted to summarize and critically appraise current evidence on the use of glucagon-like peptide-1 (GLP-1) receptor agonists, dual incretin agonists, and triple receptor agonists in the management of obesity, with a particular focus on adolescent populations